Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage
Launched by ZHONGNAN HOSPITAL · Nov 23, 2022
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a combination of two cancer treatments, docetaxel and enzalutamide, in men who have advanced prostate cancer that has become resistant to hormonal therapy after previously being treated with abiraterone. The goal is to find out if this combination can help improve patient outcomes, such as slowing down the progression of the disease, compared to using docetaxel alone.
To be eligible for the trial, participants must be men with a specific type of prostate cancer called adenocarcinoma that has spread and become resistant to hormone therapy. They should have received treatment with abiraterone before but not with enzalutamide or docetaxel. Participants can expect regular check-ups and monitoring during the trial to assess the effects of the treatments on their cancer. This trial is currently recruiting participants, and it aims to contribute valuable information about the best treatment options for men facing this challenging stage of prostate cancer.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • adenocarcinoma
- • mCRPC
- • Eastern Cooperative Oncology Group(ECOG) 0-1
- • prior Abiraterone treatment
- Exclusion Criteria:
- • prior Enzalutamide or Docetaxel treatment
About Zhongnan Hospital
Zhongnan Hospital, affiliated with Wuhan University, is a leading medical institution in China renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on multidisciplinary collaboration, the hospital employs state-of-the-art facilities and a team of highly skilled professionals to conduct rigorous clinical studies aimed at improving patient outcomes. Zhongnan Hospital prioritizes ethical standards and patient safety, ensuring adherence to regulatory requirements while fostering a culture of scientific excellence. As a prominent sponsor of clinical trials, the hospital plays a pivotal role in contributing to the global medical community and enhancing the understanding of various health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials